Abstract
Skeletal resistance to parathyroid hormone (PTH) is well defined in patients with chronic renal failure. Recently, with the increased frequency of development of adynamic bone disease (ABD), it has been suggested that higher PTH is needed to maintain bone turnover in uremia. It has very recently been argued that the optimal PTH level for maintenance of skeletal bone remodeling may be insufficient to prevent the extraskeletal complications of cardiovascular systems. Furthermore, conventional intact PTH assay detects (7-84) PTH in addition to (1-84) PTH and overestimate the actual activity of circulating PTH molecules in uremic patients. Thus, target range of PTH in uremic patients should be set by careful considerations.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
